Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Matrixx unveils 2009 launches

This article was originally published in The Tan Sheet

Executive Summary

Xcid antacid product will debut early in fiscal year 2009, and will be positioned as a better tasting product than competing antacids, the Zicam marketer announces. "Consumers perceive liquid antacid products to be highly efficacious, but they taste very bad," Matrixx President and CEO Carl Johnson notes. Xcid will come in three 'soother' flavors: Milk Chocolate, Creamy Orange and Creamy Strawberry. Products will be sold in squeezable tubes and labels will feature the statement: "from the makers of Zicam." The formula contains maximum strength ingredients calcium carbonate and magnesium hydroxide, firm notes. Matrixx also will launch Zicare, the first OTC oral care product designed to dissolve tartar, in early 2008, according to Johnson. The cinnamon-flavored adhesive gel is applied to teeth after brushing. In developing the product over the past 18 months, the company has filed seven patents and conducted clinical trials. The product will be distributed in dental offices before rolling out to retailers in coming years, the company says...

You may also be interested in...



Slow Launch Of Xcid Antacid Spurs Matrixx To Marketing Changes

Matrixx Initiatives plans product-sampling and coupon-marketing activities as well as store displays in response to "small" sales of its latest product, Xcid antacid, the firm says

‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation

CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100889

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel